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Abstract 
Recently, de novo mutations in the gene KCNA2, causing either a dominant-negative loss-of-
function (LOF) or a gain-of-function (GOF) of the voltage-gated K+ channel KV1.2, were described 
to cause a new molecular entity within the epileptic encephalopathies (EEs). Here, we report a 
cohort of 23 patients (eight previously described) with EE carrying either novel or known KCNA2 
mutations, with the aim to detail the clinical phenotype associated with each of them, to 
characterize the functional effects of the newly identified mutations, and to assess genotype-
phenotype associations. We identified five novel and confirmed six known mutations, three of 
which recurred in three, five and seven patients respectively. Ten mutations were missense and one 
was a truncation mutation; de novo occurrence could be shown in 20 patients. Functional studies 
using a Xenopus oocyte 2-microelectrode voltage clamp system revealed mutations with only LOF 
effects (mostly dominant-negative current amplitude reduction) in eight patients or only GOF 
effects (hyperpolarizing shift of voltage-dependent activation, increased amplitude) in 9 patients. In 
six patients, the GOF was diminished by an additional LOF (GOF+LOF) due to a hyperpolarizing 
shift of voltage-dependent activation combined with either decreased amplitudes or an additional 
hyperpolarizing shift of the inactivation curve. These electrophysiological findings correlated with 
distinct phenotypic features. The main differences were (i) predominant focal (LOF) vs. generalized 
(GOF) seizures and corresponding epileptic discharges with prominent sleep activation in most 
cases with LOF mutations, (ii) more severe epilepsy, developmental problems and ataxia, and 
atrophy of the cerebellum or even the whole brain in about half of the patients with GOF mutations, 
and (iii) most severe early-onset phenotypes, occasionally with neonatal onset epilepsy and 
developmental impairment, as well as generalized and focal seizures and EEG abnormalities for 
patients with GOF+LOF mutations. Our study thus indicates well represented genotype-phenotype 
associations between three subgroups of patients with KCNA2 encephalopathy according to the 
electrophysiological features of the mutations.  
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Abbreviations: KCNA2 = potassium voltage-gated channel subfamily A member 2; Kv = voltage-
gated potassium channel; WT = wild type; ADHD = attention deficit hyperactivity disorder  
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Introduction 
Epileptic encephalopathies (EEs) comprise a heterogeneous group of severe neurological disorders 
with childhood onset often characterized by severe and pharmacoresistant epilepsy and progressive 
cognitive and neurological deficits. Many genes have been identified that cause the spectrum of 
EEs, but there is a large phenotypic and genetic heterogeneity and the majority of genetic defects is 
still unknown. Genetic characterization and detailed genotype-phenotype correlations have 
contributed to the identification of specific forms of EEs, for example those associated with 
mutations of genes encoding voltage-gated ion channels, such as SCN1A, SCN2A, SCN8A, KCNQ2, 
or KCNT1. Ion channels have a central role in neuronal excitability and neurotransmitter release and 
their altered function seems to be a key factor in the etiology of genetic epilepsies (Claes et al, 
2001; Reid et al., 2009; Lerche et al., 2013; EpiK4, 2013; Carvill et al., 2013a; Møller et al., 2016; 
McTague et al., 2016). 
Recently, mutations in KCNA2 encoding the voltage-gated K+ channel KV1.2, have been reported as 
a novel cause of EE (Syrbe et al, 2015; Pena and Coimbra, 2015; Hundallah et al., 2016; Allen et 
al., 2016; Allou et al., 2016; Corbett et al., 2016). KV1.2 belongs to the KV1 family with eight 
members (KV1.1–8), all of which are expressed in the central nervous system. KV1 channels are 
composed of four subunits with six transmembrane segments each (S1-S6, see Fig. 1A; Jan and Jan, 
2012). The S4 segments form the voltage-sensor and S5-S6 the pore region. Different KV1 subunits 
can assemble in different combinations to form numerous heterotetrameric channels with different 
characteristics, such as different kinetics and voltage dependence of channel gating (Christie et al., 
1990; Sheng at al., 1994). This heteromerization can also involve assembly with auxiliary proteins 
such as KVβ subunits (Li et al., 1992). Interestingly, the KV1.2 channel forms heteromers with 
different KV subunits depending on the neuronal cell type, suggesting distinct roles of KV1.2 in 
different neuronal compartments (Sheng et al., 1994). Mice carrying a KCNA2 point mutation show 
motor incoordination, myoclonic jerks, tremor, and small body size (Xie et al. 2010) and KCNA2-
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null animals have an increased seizure susceptibility (Brew et al. 2007). Functional studies of so far 
four pathogenic KCNA2 mutations were shown to cause either a dominant-negative loss-of-
function, or a drastic gain-of-function (Syrbe et al., 2015).  
The aim of this study is to further characterize the phenotypic spectrum associated with novel or 
known KCNA2 mutations, to characterize the functional effects of newly identified mutations, and 
to assess genotype-phenotype associations with special emphasis on the differentiation of 
phenotypes due to distinct or opposite effects on protein function. 
Materials and Methods 
Patients. Fifteen new and eight previously reported patients (Syrbe et al., 2015; Pena Coimbra 
2015; Allen et al., 2016) were included in this study. The previously unreported patients were 
collected through data sharing with Epilepsy and Genetic Centers in Europe, Latin and North 
America. Clinical data for each patient were collected and categorized by using a common database. 
The database was stored at the Danish Epilepsy Centre. Wakefulness and sleep EEG data, and 
magnetic resonance imaging (MRI) scans were obtained for all patients. Seizures and where 
possible epilepsy syndromes were classified according to the latest ILAE classification proposal 
(Berg et al., 2010). The study was approved by the local ethics committees of each participating 
clinical center. Written informed consent was obtained by the parents or the legal guardian of each 
patient following local IRB requirements.  
 
Mutation analysis 
All KCNA2 variants were identified by routine genetic diagnostics performed in patients with EEs 
either by targeted gene panels or whole exome sequencing, and verified by Sanger sequencing. The 
identified KCNA2 variants were assumed to be pathogenic if they were absent in control samples 
(Exome aggregation consortium (ExAC) set of ~61,000 exomes — exac.broadinstitute.org/) and 
fulfilled one or more of the following criteria (i) had arisen de novo, (ii) found in a patient with a 
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suggestive phenotype with additional functional studies showing a clear functional effect, or (iii) 
has previously been identified as disease-causing.  
 
Functional studies 
All methods have been previously described by Syrbe et al. (2015). Experiments were approved by 
the local Animal Care and Use Committee (Regierungspräsidium Tübingen, Tübingen, Germany). 
The human KV1.2 in the pcDNA3.1 vector was kindly provided by Stephan Grissmer (Institute of 
Applied Physiology, Ulm University). Site-directed mutagenesis was performed using 
Quickchange™ (Agilent Technologies, USA; primers are available upon request). The mutated 
clones were fully resequenced. cRNA was prepared using the T7 mMessage kit from Ambion. 
Xenopus laevis oocytes were treated and stored as described. 50 nl of cRNA encoding wildtype 
(WT) or mutated KV1.2 subunits (1µg/µl) was injected using Roboocyte2 (Multi Channel Systems, 
Reutlingen, Germany). Oocytes were stored for two days (at 17°C) prior to the experiment. 
Amplitudes of currents of WT and mutant channels recorded on the same day were normalized to 
the mean value of KV1.2 WT on that day to pool normalized data from different experiments. 
Potassium currents in oocytes were recorded at room temperature (20-22°C) using two-electrode 
voltage-clamp with Roboocyte2. Electrode resistances were 0.4–1 MΩ (1 M KCl or 1.5 M KAc). 
The holding potential was –80 mV. Oocytes were perfused with a ND96 bath solution containing 
(in mM): 93.5 NaCl, 2 KCl, 1.8 CaCl2, 2 MgCl2, 5 HEPES (pH 7.6). Currents were sampled at 5 
kHz. Standard voltage-clamp protocols and analysis methods were used as described in Syrbe et al. 
(2015). All data are reported as mean ± SEM. Statistical tests were one-way ANOVA with 
Bonferroni t-test as posthoc test (for normally distributed data) or one-way ANOVA on ranks with 
Dunn’s posthoc test (for not-normally distributed data). For unpaired data sets, Student’s t-test 
(normally distributed data) or Mann-Whitney rank-sum (not-normally distributed data) were used. 
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Normality was tested using the Shapiro-Wilk test. Significance with respect to controls is indicated 
in the figures using the following symbols: *p<0.05, **p<0.01, ***p<0.001. 
 
RESULTS 
Genetics 
We describe a cohort of 23 patients (11 females, 12 males; mean age at the last follow-up: 12.9 
years (range: 4 months-37 years)) with a presumed pathogenic KCNA2 mutation (Tables 1, 2 and 
3). An additional patient was excluded by our study since it was not possible to demonstrate the 
pathogenicity of his Q357R mutation (see below). Eight patients have previously been reported 
(Syrbe et al., 2015, Pena and Coimbra, 2015; Allen et al., 2016). Ten mutations were missense: 
E157K (found in one patient), I263T (1), L290R (1), L293H (1), R297Q (7), L298F (1), L328V (1), 
T374A (3), G398C (1), P405L (5), and one (Q213*, S1/S2 loop), found in one patient, was a 
truncation mutation. The mutations occurred de novo in 20 patients; in three patients (#8, # 13, # 
16) it was not possible to test the parents (because of ovodonation in patient #13 and parental non-
availability in the others). One patient with a de novo T374A mutation had also an abnormal 
karyotype with ring chromosome 21 (p11.1q22.3) (Table 3). All the identified mutations were 
absent in ExAC and predicted to be damaging by the prediction tools Polyphen2 and Mutation 
Taster (Supplementary Table). The protein positions of the different KCNA2 mutations are shown in 
Fig. 1A. Three recurrent mutations (R297Q, T374A, P405L) account for two thirds of the 
pathogenic mutations. 
 
Functional analysis 
Ten out of 11 detected KCNA2 mutations were located in highly conserved and functionally 
important protein regions (Fig. 1A). Only the mutation found in patient #18 (Q357R) affected a less 
  11 
 
conserved part of the pore region (Fig. 1B). The others were located in the N-Terminus (E157K), 
the S3 segment (I263T), the voltage-sensor (L290R, L293H, R297Q and L298F), S5 (L328V), the 
pore region (T374A) or in the S6 segment (G398C and P405L) (Fig. 1A). If not indicated 
otherwise, the same total amount of cRNA encoding the WT KV1.2 channel, mutants or their 
mixtures were injected and recordings were made in parallel two to three days after injection.  
Mutations causing loss-of-function (LOF) effects: We have previously shown that the I263T and 
P405L mutations are associated with a less severe phenotype and cause a loss-of-function (Syrbe et 
al., 2015). The mutation Q213* identified in patient #1 is predicted to either lead to nonsense-
mediated mRNA decay or to truncate the channel early in the transmembrane region (S1/S2 loop), 
long before important phosphorylation sites in the C-terminus controlling KV1.2 trafficking (Yang 
et al., 2007, see also discussion). Therefore, it was assumed that it results in a loss-of-function. 
G398C, which was newly identified in patient #3, was also predicted to have a LOF effect as 
previously reported for KV1.1 channels (Upadhyay et al., 2009; Yifrach and MacKinnon, 2002). 
When we expressed G398C mutant KV1.2 channels in Xenopus laevis oocytes, the recorded K
+ 
currents were not significantly larger than background level, similar to those reported previously for 
I263T and P405L mutant channels (Syrbe et al., 2015). However, in contrast to I263T and P405L, 
we did not detect a dominant-negative effect of G398C on WT channels in co-expression 
experiments (Fig. 2A,B). 
Mutations causing gain-of-function (GOF) effects: For the R297Q mutation, affecting the second 
arginine of the voltage sensor, and the neighboring L298F, we have shown recently a dominant 
GOF effect with up to 13-fold increased current amplitudes and a shift of steady-state activation by 
-40 to -50 mV compared with WT channels (Syrbe et al., 2015). Here, we also identified the E157K 
mutation as GOF: this mutation, located in the N-terminus of the channel, caused a dominant GOF 
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with a 5-fold increase in current amplitudes (Fig. 2A,D), a hyperpolarized resting membrane 
potential (Fig. 2C), and a less pronounced shift of steady-state activation by -12 mV (Fig. 2E).   
In contrast to the GOF effect of mutations located in highly conserved regions of the channel, the 
Q357R variant, located in a less conserved part of the pore region and for which a de novo status 
remained unclear, did not show any detectable functional changes (see Supplementary Table). Due 
to the drastic changes of all other mutations, we rather consider this variant as a benign 
polymorphism which is not responsible for the clinical phenotype of the patient, although the 
phenotype fits well with a GOF KCNA2 mutation and we cannot exclude that we missed an 
alteration with our experimental system. The patient #18, carrying the Q357R variant is not 
included in our analysis, however, his phenotype is described in the Supplementary Note.  
Mutations causing GOF+LOF effects: We also found hyperpolarizing shifts of the activation curves 
for L290R and L293H, located in S4 (Fig. 1A and Fig. 3D), which predict a GOF effect with 
permanently open mutant channels under physiological conditions. In contrast to E157K, R297Q 
and L298F, however, inactivation curves were also shifted to more hyperpolarized potentials 
predicting a LOF effect with less steady-state availability for larger depolarizations. These shifts 
were less pronounced for L290R than for L293H, but there was a markedly decreased steepness of 
both activation and inactivation curves for L290R channels suggesting an enhancement of the GOF 
effect on activation and a reduction of the LOF effect on inactivation in the physiologically most 
relevant voltage range near the resting membrane potential (Fig. 3D,E, Supplementary Table). In 
addition, L290R mutant channels yielded significantly larger current amplitudes (Fig. 3A,C), 
another GOF effect. Although the negative shifts of steady-state inactivation diminish the GOF 
effect on activation and amplitude, resting membrane potentials were significantly more negative in 
oocytes injected with mutant compared to WT cRNA (Fig. 3B). This indicates a net and dominant 
GOF effect at resting conditions for those two mutations.  
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Furthermore, we found mutations in S5 or the pore region of the channel that were predicted to have 
a GOF effect from functional studies of KV1.1, a highly conserved channel from the same family 
(L328V; Upadhyay et al., 2009), and its drosophila homolog shaker (T374A; Yool and Schwarz, 
1995; Heginbotham et al., 1994, Zheng and Sigworth, 1997). L328V (located in S5) caused a -20 
mV shift of steady-state activation and more negative resting potentials in injected oocytes 
compared to the WT (Fig. 3 F,G,I and Supplementary Table). However, current amplitudes were 
decreased in contrast to the S4 mutations, even exerting a slight dominant-negative effect on the 
WT, which should reduce the GOF (Fig. 3H and Supplementary Table). The mutation T374A, 
which was found in three patients (#22, #23, #24) with the most severe phenotype (see phenotypic 
descriptions below), caused a more prominent combination of both GOF and LOF effects. This 
mutation was located in a highly conserved part of the pore region, which has been shown to be 
essential for K+ selectivity (Heginbotham et al., 1994). It caused a GOF effect, by a similar -20 mV 
shift of the activation curve as L328V; however, the resting potential of injected oocytes was much 
less negative than for L328V and there was a more prominent decrease in current amplitude with a 
dominant-negative effect (Fig. 3G,H, Supplementary Table).  
Therefore, the functional analysis showed that in the group of GOF mutations, some had prominent 
GOF effects only (E157K, R297Q, L298F) whereas others displayed a combination of both GOF 
and LOF effects (GOF+LOF) (L290R, L293H, L328V, T374A).  
 
Phenotypic characterization and genotype-phenotype associations 
Our previous data indicate that the phenotypes associated with KCNA2 mutations may be 
differentiated into two main groups, based on the severity of the encephalopathy and of the seizure 
disorder, with the milder phenotype correlating with LOF mutations and more severe phenotypes 
with GOF mutations (Syrbe et al., 2015). To further explore this initial impression, we illustrate the 
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phenotypic features of our patients with LOF KCNA2 mutations separately from the patients with 
GOF KCNA2 mutations. Since some of the GOF mutations also showed some additional LOF 
effects, we further subgroup those patients carrying mutations with similar electrophysiological 
properties. 
Phenotypic features of patients with LOF KCNA2 encephalopathy (Table 1). Eight patients 
presented with LOF KCNA2 mutations. The mean age at seizure onset was 8.4 months (range: 2-17 
months), with prior cognitive and motor development reported as normal in all patients. At onset, 
febrile seizures were reported in 3/8 patients, one of them (#6) presenting with prolonged 
convulsive febrile status epilepticus. Seizure semiology at onset was consistent with focal seizures 
in six patients, four of them presenting with hemiclonic seizures which in two subjects (#4 and #5) 
were preceded by eye-deviation and vomiting. Eye deviation as ictal feature was reported also in 
patient #1 (Q213* mutation). With increasing age, 6/8 of them developed focal dyscognitive 
seizures and focal motor seizures with possible secondarily generalized tonic-clonic seizures 
(sGTCS); in three of them (#3, #7, #8) generalized seizures were also observed. Only patient #2 
(carrying the I263T mutation) presented with generalized seizure types, including myoclonic 
seizures at onset and myoclonic-atonic seizures later on. Post-ictal hemiparesis was reported in two 
patients (#4 and #6), both featuring hemiclonic or focal motor seizures with or without sGTCS. The 
course of epilepsy was relatively favourable in most of the patients compared to those with GOF or 
GOF+LOF mutations. Four of eight patients became seizure-free (mean follow-up 4 years; range 
1.5-6 years), and one patient (#7) continued to have rare absences. Three patients continued to have 
daily atypical absences (#8), multiple seizure types (#3) or uncontrolled focal seizures (#1). All 
patients are still on anti-epileptic medications, two of them on monotherapy.  
Epilepsy onset was accompanied or followed by a delay or a stagnation of psychomotor 
development in all patients. The neurological picture worsened over time, mainly because of the 
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appearance of impairment of fine motor skills (7 patients), ataxia (6), poor coordination (6), or 
dysarthria (2). Additional motor symptoms were fine continuous finger myoclonia 
(“polyminimyoclonus”) (2), hand tremor (2), or dyskinesia (1). All patients were cognitively 
impaired with mild-to-moderate intellectual disability (ID) in 5 patients, three of them (#2, #4, #6) 
presenting also with language problems. Patients #1, #7 and #8 had severe intellectual disability 
with delayed or absent language acquisition. Behavioural disturbances including aggressiveness, 
irritability or hyperactivity were reported in two patients (#6 and #7). Autism spectrum disorders 
were diagnosed in patient #3 (associated with obsessive compulsive disorder) and #8; patient #1 
was reported to have stereotypies. Variable additional symptoms such as endocrinological 
dysfunction (growth-hormone deficiency and subclinical hypothyroidism) (1 patient), scoliosis (1), 
pes planus and osteoarthritis (1), osteoporosis (1), or sensori-neural hearing loss (1) were observed. 
Overall the clinical pictures of patient #2, #4, #5, and #6 (three carrying the P405L and one the 
I263T mutation) were relatively mild and homogeneous with similar age of onset, benign course of 
epilepsy, mild to moderate ID and neurological compromise, whereas patients #1 (Q213*), #3 
(G398C), and #7 and #8 (both with P405L) differed from the other patients due to more severe ID 
with behavioral disturbances, more prominent motor/coordination dysfunction, and incompletely 
controlled epilepsy.  
EEG at onset in 5 patients (#2, #4, #5; #6, #8) showed a peculiar pattern characterized by focal, 
mainly central or posterior-temporo-occipital sharp-slow waves and clusters of polyspikes, that 
tended to spread to fronto-prefrontal regions (Fig. 4). Multifocal sharp waves combined with 
generalized paroxysms were observed in two patients (#3 and #7), both presenting with focal and 
generalized seizures; patient #1 had multifocal spike-waves. Dramatic activation of EEG 
abnormalities during sleep (up to 100% of NREM sleep), featuring diffuse epileptic discharges with 
posterior predominance, was reported in four patients (#4, #5, #6, #8), associated with worsening of 
the cognitive status and deterioration of language in patient #6, reminiscent of the syndrome of 
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encephalopathy with status epilepticus during slow sleep (ESES) (Tassinari et al., 2012) 
(Supplementary Fig.1). In this latter patient, normalization of the EEG at the age of 17 years was 
associated with an improvement of language, further supporting a diagnosis of ESES during the 
active phase of the sleep EEG. In the other three patients (#4,#5,#8) the difficulties to ascertain a 
deterioration of the pre-existent cognitive status during the activation of epileptiform activity in 
sleep EEG, and the lack of a longitudinal neuropsychological evaluation did not allow to conclude 
that these patients suffered from ESES. As a whole, in all subjects the EEG abnormalities were 
more abundant in the infantile and childhood age. MRI was unremarkable in all patients. 
Phenotypic features of patients with GOF KCNA2 encephalopathy (Tables 2&3). Fifteen patients 
presented with GOF mutations, including a subgroup showing GOF+LOF effects. We here present 
the phenotypes of patients with mutations with GOF effects only separately from those with 
GOF+LOF effects. Patient #18 carrying the Q357R mutation without a functional effect is not 
included in this analysis and his phenotype is presented in the Supplementary Note. 
Phenotypic features of patients carrying mutations with GOF effects only (Table 2): Nine patients 
carried such GOF mutations. The mean age of seizure onset was 8.7 months (range: from 5 to 15 
months, except patient #14 starting at birth with episodes of extension or flexion of the  limbs and 
head interpreted as infantile spasms). Epilepsy onset was characterized by febrile convulsive 
seizures or febrile status epilepticus in 5/9 patients. The remaining four patients presented at onset 
with absences or afebrile GTCS, and #14 with infantile spasms. During development, all patients 
presented with generalized seizure types, such as typical or atypical absences, myoclonic seizures, 
and GTCS. Epileptic seizures were not controlled in 8/9 patients; seizure frequency varied from 
daily absences or weekly GTCS to monthly or even more sporadic seizures (once per year in patient 
#10). One patient (#13) became seizure-free (the follow-up was at 3.5 years). The majority of 
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patients was on polytherapy, whereas only two were on monotherapy; in none was medication 
stopped. 
All patients had a developmental delay during the course of the disease, including patients with 
primary developmental delay and patients with developmental plateauing following an initial 
unremarkable development. Additional neurological features developed over time including ataxia 
(9 patients), impairment of fine or gross motor skills (5), tremor (5), dysarthria (4), hypotonia (4), 
pyramidal signs (4), dysdiadochokinesis (2), or myoclonus (1). The severity of ataxia ranged from 
mild-moderate (patients #9, #11, #16) to severe with inability to walk unassistedly (patient #17). 
Pyramidal signs were usually mild, such as a positive Babinsky sign or a modest impairment of fine 
motor skills. All patients had cognitive impairment ranging from moderate intellectual disability 
with delayed language acquisition (patients #9-13, #16) to severe intellectual disability (patients 
#14-15) without language acquisition (patient #17). Behavioral features such as hyperactivity, 
stubbornness, and aggressiveness were reported in five patients (#9-#13); autistic spectrum disorder 
was reported only in one patient (patient #15). 
Craniofacial dysmorphisms including a wide forehead, deep-set eyes with synophris, a bulbous 
nasal tip or beaked nose, or microcephaly were observed in two patients (#16 and 17), kyphosis and 
genu valgum were reported in patient #12. Patient #16 presented with scoliosis.  
The main EEG features in 9/9 (100%) patients were background slowing with generalized spike-
polyspike-waves or generalized sharp and slow-waves. In the older patients, the bursts of 
generalized epileptiform discharges were less frequent and tended to be more prominent with 
highest amplitude over the midline (Fig. 5). Four patients (#9,#12,#13,#16) showed additional focal 
or multifocal epileptiform discharges.  
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MRI in adult patients showed mild to severe cerebellar atrophy (four patients) (Supplementary 
Fig.2). Unremarkable MRIs were reported in childhood suggesting that cerebellar atrophy might 
appear later in the course of the disease.  
Phenotypic features of patients carrying mutations with GOF+LOF effects (Table 3). Six patients 
presented with mutations showing both GOF and LOF effects. The mean age at seizure onset was 
2.1 months (range: from birth to 6 months). Fever sensitivity was reported only in one patient (#21). 
Generalized seizures such as myoclonic seizures, tonic seizures or GTCS were reported at the onset 
and throughout the evolution in 3/6 patients, whereas the remaining three presented with focal 
seizures. Patient #22 presented also with episodes of extension or flexion of the limbs and head, and 
eye deviation that were diagnosed as infantile spasms. Seizures persisted with variable frequency 
ranging from sporadic or weekly GTCS to daily absences. The majority of patients were on 
polytherapy. None of the patients achieved seizure freedom. A prolonged period of seizure freedom 
was seen in a 4-month old child (#24) after the introduction of topiramate; however the follow-up 
period of 5 months was too short to establish whether he achieved long-standing seizure control. 
Developmental delay was reported in all patients, preceding the seizure onset in 3/6 patients. At the 
time of the last follow-up, 5/6 patients had severe or profound ID; three of them were non-verbal 
(#20, #22, #23). Additional neurological features included ataxia (3), hypotonia (2), tremor (2), 
dysarthria (1). Two patients (#22 and #23) with a T374A pathogenic variant showed a more severe 
phenotype with profound ID, lack of language acquisition, spastic tetraplegia, optic atrophy, and 
severe scoliosis. A third patient (#24) with this mutation was too young at the last follow-up (5 
months old) to fully assess disease severity, however he presented with neonatal epilepsy, primary 
severe developmental delay, hypotonia, choreoathetosis, myoclonus and lack of fixation. 
Behavioural features such as ADHD and hyperactivity were reported in three patients (#19, #20, 
#21). One of the three patients carrying the T374A mutation (#22) was found to have also ring 
chromosome 21. However, considering the striking similarity of his phenotype with the other two 
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patients carrying the same mutation, we concluded that the clinical picture was likely contributed 
primarily by the KCNA2 mutation. 
Craniofacial dysmorphisms such as microcephaly, or brachycephaly with occipital plagiocephaly 
were observed in patients #20, #22 and #23. Scoliosis was reported in patients #22 and #23. In all 
patients, EEG showed focal or multifocal spikes or sharp waves. Discharges were more frequent in 
the posterior regions (Fig.5), associated with generalized spike-waves in 2/6 patients. Brain MRI 
showed cerebellar atrophy in three patients (#21-23; in patient 22 associated also with cerebral 
atrophy) (Supplementary Fig.2) at a younger age as compared with patients carrying mutations with 
GOF effects only.  
In summary, the subgroup of patients carrying mutations with GOF+LOF effects presents 
distinctive features compared to the subgroup with GOF effects only, such as: a) an earlier age of 
seizure onset, rarely triggered by fever; b) propensity to present either with focal or with 
generalized seizures; c) a higher incidence of focal EEG epileptic discharges; d) more severe 
neurological and more pronounced intellectual disability, and e) MRI evidence of cerebellar atrophy 
at an earlier age. 
 
Discussion 
Our study including a large number of new patients and novel mutations has three major results for 
KCNA2-related encephalopathy. First, it detects a new class of mutations not exhibiting either a 
GOF or LOF effect on channel function, but a combined GOF+LOF. Second, it widens the clinical 
spectrum of this new disease entity and now distinguishes three groups of clinical phenotypes which 
are related to the functional effects on protein function (LOF only, GOF only, and GOF+LOF). 
Third, in each of these three categories one mutation recurs with a strikingly homogeneous 
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phenotype in most patients (P405L, R297Q and T374A). Two thirds of all patients with KCNA2 
encephalopathy reported so far, 10 new patients from this study and seven from previous ones 
(Syrbe et al., 2015; Pena and Coimbra, 2015; Hundallah et al., 2016; Corbett et al., 2016), carried 
one of these three mutations. Furthermore, KCNA2 mutations arose de novo in all patients in whom 
it could be tested (20/23). 
On one hand, the three phenotypic groups shared common clinical features, and on the other they 
showed several distinctive characteristics and different degrees of disease severity. Common 
phenotypic features were the early age of epilepsy onset, fever sensitivity, cerebellar involvement, 
cognitive and language impairment and behavioural disorders. Onset of epilepsy occurred within 
the first to second year of life, while the GOF+LOF subgroup showed the earliest, often neonatal 
onset. Febrile seizures or febrile status epilepticus at onset occurred in a similar proportion in the 
LOF or GOF groups, but less in the GOF+LOF group. Cerebellar involvement was one of the 
prominent characteristics of KCNA2 encephalopathy. Ataxia was reported in the majority of 
patients in both groups, although the degree of severity was much more pronounced in the GOF 
group, in which some patients were unable to walk without support. Other cerebellar features 
observed in all patients were impaired coordination and dysarthria, whereas hypotonia and tremor 
were reported mainly in the GOF subgroup. Intellectual disability was observed in all patients, but 
the cognitive impairment was much more severe in patients carrying GOF mutations compared to 
patients with LOF mutations. Various degrees of language impairment were reported in almost all 
patients, without overt differences between LOF and both GOF subgroups with regards to the 
proportion of non-verbal patients. Finally, behavioural features such as aggressiveness and 
irritability were reported in patients from both groups, whereas stubbornness and hyperactivity 
associated with moderate intellectual disability characterized mainly the GOF group.  
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In addition to common symptoms with a different degree of severity, there were several distinctive 
features that differentiate the phenotypes associated with LOF or GOF only, or with GOF+LOF 
mutations, including seizure types, EEG features, epilepsy outcome, and neuroimaging. In the GOF 
only group, the seven patients carrying the same R297Q mutation presented a homogeneous 
epilepsy phenotype characterized by generalized seizures such as typical and atypical absence 
seizures, myoclonic seizures and GTCS, in agreement with the EEG data showing generalized 
epileptic discharges in all of them. Also patient #17 carrying the pathogenic variant L298F showed 
features of a generalized epilepsy, however, the neurological picture was more severe as compared 
to R297Q. Only patient #9 with the E157R GOF mutation presented with both focal (motor) and 
generalized (atypical absences) seizures, and a mixture of focal and generalized epileptic discharges 
on EEG.  
In the GOF+LOF subgroup, patients presented in equal proportion with either focal or generalized 
seizures. Interestingly, all three patients presenting with focal seizures (#22, #23, #24) shared the 
same recurrent mutation (T374A) and the associated phenotypes were more severe than any of the 
other KCNA2-related phenotypes described so far, including profound ID, spastic tetraplegia, 
hypotonia, intractable epilepsy, choreoathetosis, microcephaly and optic atrophy. Hundallah et al 
(2016) recently reported a patient with a similar phenotype and the same KCNA2 mutation. In 
patient #22, the contribution of ring chromosome 21 to the phenotype was difficult to assess, since 
the clinical picture associated with this chromosomal abnormality can be extremely variable, 
ranging from normal intellect to severe psychomotor retardation, with impaired speech, epilepsy, 
hypotonia, and craniofacial dysmorphisms including microcephaly (Specchio et al., 2011). Some of 
these features are also shared by patients with KCNA2 encephalopathy. The striking similarity of 
the phenotype of patient #22 with that of patients #23 and 24#, carrying the same KCNA2 mutation, 
suggest that the clinical phenotype of patient #22 was mainly determined by the KCNA2 mutation. 
The T374A mutation showed a GOF with the strongest LOF in combination, i.e. a dominant-
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negative amplitude reduction. This peculiar electrophysiological feature may thus be specific for a 
particularly severe subgroup of patients with KCNA2 encephalopathy. 
Most of the patients with LOF mutations had focal seizures with the only exception of patient #2 
who presented with generalized (myoclonic and myoclonic-atonic) seizures. In addition, we found 
that three LOF patients (#4, #5, #6) with the same mutation (P405L) had similar focal seizures types 
including focal dyscognitive seizures and hemiclonic seizures, sometimes evolving to secondary 
generalization or even to status epilepticus, followed by post-ictal paresis in two of them. Moreover, 
two of these patients presented at epilepsy onset with seizures characterized by eye deviation, 
vomiting, prolonged hemiclonic jerks: these features may be consistent with a focal onset in 
posterior brain regions (Sveinbjornsdottir and Duncan, 1993), in agreement with the EEG finding of 
epileptic abnormalities in temporo-occipital regions. Only one patient with a LOF mutation (#7) 
suffered from both focal and generalized seizures with generalized and multifocal EEG epileptic 
abnormalities, in the context of a very severe phenotype that included severe intellectual disability, 
behavioural disturbances, and additional symptoms such as sensorineural hearing loss. It is worth to 
note that some phenotypic features of LOF patients (i.e., infantile or early-childhood seizure onset, 
febrile and afebrile hemiclonic or myoclonic seizures, focal motor seizures, and status epilepticus) 
can overlap with Dravet syndrome, thus including KCNA2-LOF encephalopathy in the phenotypic 
spectrum of the Dravet-like conditions.  
An EEG feature only seen in LOF patients was the propensity for striking activation of the 
epileptiform activity during NREM sleep (pts #4, #5, #6, #8). This finding and the concomitant 
further deterioration of language and cognitive/behavioral status, raises the concern for ESES in 
KCNA2-LOF patients (Tassinari et al., 2012). This possibility is corroborated by patient #6, in 
whom the improvement of the sleep EEG was associated with a partial recovery of language. 
Therefore, in KCNA2-LOF patients, further deterioration of the cognitive and behavioural status 
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during the course of the disease warrants a proper electro-clinical assessment to detect the possible 
occurrence of ESES. Further evidences are necessary to designate KCNA2 mutations as a possible 
genetic cause of ESES. P405L was the most common LOF pathogenic variant being associated with 
the typical features of a normal development before disease onset, focal motor and hemiclonic 
seizures, posterior EEG abnormalities, occurrence of an ESES-like EEG pattern during sleep, and 
response to treatment in 4/5 patients. 
Epilepsy outcome also distinguishes the LOF vs GOF groups, with a relatively favorable course in 
patients with LOF mutations with 4/8 patients becoming seizure-free. Pharmacoresponsive epilepsy, 
associated with episodic ataxia, has been reported also in a novel KCNA2 pathogenic variant 
(255_257del) with a LOF effect (Corbett et al., 2016). In contrast, only 1/9 patients with GOF 
mutations became seizure-free, and none with a GOF+LOF mutation, even though the severity and 
frequency of seizures decreased in most patients over time.  
The presence of cerebellar atrophy was a further distinguishing feature between the three subgroups 
of patients, with marked cerebellar atrophy in about half of patients with GOF mutations. In 
contrast, brain MRI was unremarkable in patients with LOF mutations. In the GOF+LOF subgroup, 
the cerebellar atrophy was detected already in childhood, whereas in the GOF only group it was 
observed only in adulthood. This suggests that the degree of cerebellar atrophy correlates with 
particular electrophysiological characteristics of the underlying KCNA2 pathogenic variants. Spastic 
tetraplegia was observed only in patients with GOF pathogenic variants; this feature has not been 
reported so far in KCNA2 encephalopathy. However, spastic paraplegia has been recently associated 
with a specific KCNA2-LOF variant with a probable additional electrophysiological defect of a 
proton current through the gating pore of the voltage sensor (Helbig et al., 2016). Finally, facial 
dysmorphism (mostly broad forehead), microcephaly, and orthopedic abnormalities (scoliosis, 
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kyphosis, genu valgum) were detected mainly in the GOF subgroup, whereas patient #4 with a LOF 
mutation had short stature and growth hormone deficiency. 
There are specific mutations, which were associated with distinct phenotypes, such as the T374A 
which caused the most severe phenotype with neonatal epilepsy onset with both generalized and 
focal features, the R297Q which was characterized by moderate/severe degrees of intellectual 
disability and generalized seizures, and the P405L mutation which was associated with a milder 
phenotype with focal epilepsy. Thus, there is evidence emerging from our data that at least in some 
cases the specific mutation itself is largely responsible for specific clinical symptoms. However, 
there were some patients deviating from this pattern suggesting that other environmental factors or 
the genetic background also influence the phenotype.  
Our electrophysiological studies indicate that all mutations with any GOF effect hyperpolarize the 
membrane potential of oocytes and may therefore inhibit the firing of neurons expressing these 
mutations (‘electrical silencing’). It is tempting to speculate that inhibitory neurons may play a 
major role in this case to generate seizures. This hypothesis fits well with the observation that 
inhibitory neurons are primarily affected in many generalized epilepsies (GABA receptor mutations 
associated with generalized genetic epilepsies or GEFS+, Dravet syndrome and GEFS+ associated 
with mutations in SCN1A encoding the main Na+ channel in inhibitory neurons, KCNC1 mutations 
in progressive myoclonic epilepsy, PTZ model of acute generalized epilepsy) (Reid et al., 2009; 
Coppola and Moshe, 2012; Lerche et al., 2013; Muona et al., 2015). In contrast, LOF mutations 
predict an impaired repolarization of an action potential and neuronal hyperexcitability (McNamara 
et al. 1996, Robbins et al. 2012), which may primarily affect the excitatory pathway. This would 
strengthen the hypothesis of a primarily glutamatergic impairment in many focal epilepsies, such as 
SCN2A mutations in BFNIS or NMDA receptor mutations in genetic focal epilepsies, or the kainate 
model of acute seizures (Liao et al., 2010, Lemke et al., 2013; Lesca et al., 2013; Carvill et al., 
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2013b; Levesque and Avoli, 2013). Both GOF and LOF effects on KV1.2 channels could also 
impact the expression of heteromeric KV1.2-containing Kv1 channels, alter the excitability of 
specific neuronal compartments of different cell types (Manganas et al., 2001, Sheng et al., 1994) 
and thus cause a specific phenotype. For the truncation mutation Q213* two different scenarios 
could be possible, which cannot be predicted: the mutation could either (i) turn on nonsense-
mediated mRNA decay leading to degradation of the mRNA or (ii) a deleterious truncated protein 
can be translated. The truncated protein not only causes a complete LOF of KV1.2 channels 
(translated protein stops long before the C-terminal phosphorylation sites that are essential for 
trafficking), but could also impact trafficking of heteromeric KV1.2-containing Kv1 channels to the 
cell membrane (Yang et al., 2007). Therefore, further detailed studies in neurons and animal models 
are required to unravel the real consequences of KCNA2 dominant LOF and GOF mutations in 
neurons and understand the pathophysiology on a network and behavioral level. 
There are two mouse models that have been studied with genetic alterations in KCNA2, a 
spontaneous point mutation (Pingu mouse) causing cerebellar ataxia (Xie et al. 2010), and a knock-
out model (Brew et al. 2007). KV1.2 channels are highly expressed in the cerebellum. In Pingu 
mice, the KV1.2 mutant channel reduces the spike output of Purkinje cells, which could explain the 
ataxia, and transgenic overexpression of KCNA2 could rescue coordinated motor control (Xie et al. 
2010). Mice lacking KV1.2 displayed increased seizure susceptibility and premature death (Brew et 
al. 2007). However, these models are only insufficiently representing the effects of KCNA2 
mutations observed in our patients, since the dramatic biophysical consequences we showed on the 
channel level were much different from those described for the Pingu mutation (Xie et al. 2010) or 
from a knock-out (Brew et al. 2007).  
In conclusion, our study provides evidence for specific symptoms and significant genotype-
phenotype correlations in KCNA2 encephalopathy. This suggests that different pathophysiological 
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mechanisms correspond to distinct clinical presentations. Additional clinical, genetic and 
pathophysiological studies may further corroborate our findings and provide useful information to 
predict the disease course and to orient targeted treatments. 
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Figure legends 
Fig. 1: Mutations affecting the KV1.2 potassium channel. (A) Structure of the voltage-gated 
potassium channel KV1.2 with transmembrane segments S1-S4 forming the voltage sensor domain 
(light gray) and segments S5 and S6 forming the pore region (dark gray) with its pore-forming loop. 
All variants (except the truncation mutation Q213* in blue and Q357R in green) are localized to 
highly conserved regions in the N-Terminus (E157K, yellow), the S3 segment (I263T, gray box), 
the S4 segment constituting the voltage sensor (L290R, red; L293H, orange; R297Q, light gray 
triangle; L298F, dark gray triangle), the S5 segment (L328V, dark red), the pore region (T374A, 
yellow) and the S6 segment (G398C, blue box; P405L, light gray box). Loss of function (LOF) are 
shown as boxes in blue shades, gain of function (GOF) mutations as triangles in yellow shades, and 
GOF+LOF mutations as circles in red shades. Already published mutations are shown in gray with 
the corresponding symbol. (B) Mutant amino acid positions and their respective surrounding amino 
acids. All variants except Q357R show evolutionary conservation.  
 
Fig. 2: Functional effects of the LOF-KCNA2 mutation encoding G398C and the GOF-KCNA2 
mutation encoding E157K. (A) Representative current traces of KV1.2 wildtype (WT, left), KV1.2 
G398C (right) and KV1.2 E157K (bottom) channels recorded in a Xenopus oocyte during voltage 
steps (from −80 mV to +70 mV). (B) Mean potassium current amplitudes were significantly 
reduced for G398C mutants in comparison to the WT channel (WT, n=6; G398C, n=6). Current 
amplitudes of mutant channels were similar to those recorded in oocytes injected with water (n=5). 
Coexpression of G398C and WT channel did not show any effect of the mutation on the WT (in a 
1:1 ratio of cRNA amount injected into the oocytes; n=6). Shown are means ± s.e.m. Statistically 
significant differences between WT channels and the tested groups were verified by ANOVA on 
ranks (P < 0.001) with post-hoc Dunn’s method (P < 0.05) (indicated by asterisks). (C) Resting 
membrane potentials of oocytes injected with WT (1.0, n = 15), E157K (1.0; n = 20) or WT + 
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E157K (1:1, n = 14). Shown are means ± s.e.m. Statistically significant differences between WT 
channels and the tested groups were verified by one-way ANOVA on ranks (P < 0.001) with post-
hoc Bonferroni t-test (P < 0.05) (indicated by asterisks). (D) Mean current amplitudes of oocytes 
injected with WT (1.0, n = 15), E157K (1.0, n=20) and WT + E157K (1.0:1.0, n = 27). Shown are 
means ± s.e.m. There was a statistically significant difference between WT channels and the tested 
groups (one-way ANOVA, (P < 0.001) with post-hoc Bonferroni t-test (P < 0.05) (indicated by 
asterisks)). (E) Mean voltage dependence of KV1.2 channel activation for E157K channels together 
with the activation curves for WT and coexpressed channels (1:1 ratio). Shown are means ± s.e.m. 
Lines represent Boltzmann functions fit to data points. The activation curves were significantly 
shifted to more hyperpolarized potentials for all mutations (P < 0.05).  
 
Fig. 3: KCNA2 mutations can cause gain and loss of function. (A) Representative current traces of 
KV1.2 WT (left), KV1.2 L290R (middle) and KV1.2 L293H (right) channels recorded in a Xenopus 
oocyte during voltage steps (from −100 mV to +70 mV). (B) Resting membrane potentials of 
oocytes injected with WT (1.0, n = 33), L290R (1.0; n = 8), WT + L290R (0.5:0.5, n = 6), L293H 
(1.0; n = 6) or WT + L293H (1:1, n = 21). Shown are means ± s.e.m. Statistically significant 
differences between WT channels and the tested groups were verified by one-way ANOVA on 
ranks (P < 0.001) with post-hoc Bonferroni t-test (P < 0.05) (indicated by asterisks). (C) Mean 
current amplitudes of oocytes injected with WT (1.0, n = 33), L290R (1.0, n= 8), WT + L290R 
(0.5:0.5, n = 6), L293H (1.0; n = 6) or WT + L293H (0.5:0.5, n = 21). (D) Mean voltage 
dependence of KV1.2 channel activation for WT, L290R and L293H channels. Shown are means ± 
s.e.m. Lines represent Boltzmann functions fit to data points. The activation curves were 
significantly shifted to more hyperpolarized potentials for all mutations (P < 0.05). (E) Mean 
voltage dependence of KV1.2 channel inactivation for WT, L290R and L293H mutants. Shown are 
means ± s.e.m fitted to a standard Boltzmann function. Inactivation curves of L290R and L293H 
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channels are significantly shifted to more hyperpolarized potentials in comparison to the WT. 
Statistically significant differences between WT channels and the tested groups for (C) to (E) were 
verified by ANOVA on ranks (P < 0.001) with post-hoc Dunn’s method (P < 0.05). Shown are 
means ± s.e.m. (F) Representative current traces of KV1.2 WT (left), KV1.2 L328V (middle) and 
KV1.2 T374A (right) channels recorded as described in Fig. 2A. (G) Resting membrane potentials 
of oocytes injected with WT (1.0, n = 54), L328V (1.0; n = 12), WT + L328V (1:1, n = 20), T374A 
(1.0, n = 19) or WT + T374A (1:1, n = 23). Shown are means ± s.e.m. Statistically significant 
differences between WT channels and the tested groups were verified by one-way ANOVA (P < 
0.001) with post-hoc Bonferroni t-test (P < 0.05) (indicated by asterisks). (H) Mean current 
amplitudes of oocytes injected with WT (1.0, n = 54), L328V (1.0; n = 12), WT + L328V (1:1, n = 
20), T374A (1.0, n = 19) or WT + T374A (1:1, n = 23). Shown are means ± s.e.m. (I) Mean voltage 
dependence of KV1.2 channel activation for L328V (closed symbols) and T374A (open symbols) 
channels together with the activation curves for WT (black) and coexpressed channels (1:1 ratio, 
indicated as dotted lines) for each of the mutations. Shown are means ± s.e.m. Lines represent 
Boltzmann functions fit to data points. The activation curves were significantly shifted to more 
hyperpolarized potentials for all mutations (P < 0.05). Statistical significant differences between 
WT channels and the tested groups of (H) and (I) were tested using ANOVA on ranks (P < 0.001) 
with post-hoc Dunn’s method (P < 0.05). 
 
Fig.4: EEG features of four patients with KCNA2–LOF mutations (pts #4, #5 and #6 carry a P405L 
mutation). The interictal EEG showed a pattern of recurrent sharp and slow waves or spike and 
waves alternated with short bursts of polyspikes at about 8-10 Hz (in pt #2 was about 18-20 Hz), 
lasting about 200 ms-1 s, over both temporo-parieto-occipital regions, synchronous or asynchronous 
in both hemispheres. 
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Fig.5: EEG features in patients with KCNA2-GOF and KCNA2-GOF+LOF mutations 
Upper panel: Interictal EEG of two patients carrying the same KCNA2-GOF mutation (R297Q) at 
different ages. In pt #13 (5 years old), the EEG features were background slowing, delta activity 
and spikes and slow waves bilaterally in the occipital regions and bursts of generalized 
spike/polyspike-and-slow wave complexes. In pt #12 (37 years old), the EEG shows sub-continuous 
theta and beta activity in the midline, intermixed with 3-5Hz positive spikes, with accentuation and 
bilateral spreading during drowsiness and sleep.  
Lower panel: Interictal EEG features in a 5-years old patient (# 23), carrying a KCNA2 GOF+LOF 
mutation (T374A).  During wakefulness (left), the EEG shows multifocal abnormalities with 
predominance over both temporo-parieto-occipital regions, with striking accentuation during sleep 
(right).  
 
